203 related articles for article (PubMed ID: 31903848)
1. Bridging inhaled aerosol dosimetry to physiologically based pharmacokinetic modeling for toxicological assessment: nicotine delivery systems and beyond.
Kolli AR; Kuczaj AK; Martin F; Hayes AW; Peitsch MC; Hoeng J
Crit Rev Toxicol; 2019 Oct; 49(9):725-741. PubMed ID: 31903848
[TBL] [Abstract][Full Text] [Related]
2. Deconvolution of Systemic Pharmacokinetics Predicts Inhaled Aerosol Dosimetry of Nicotine.
Kolli AR; Calvino-Martin F; Kuczaj AK; Wong ET; Titz B; Xiang Y; Lebrun S; Schlage WK; Vanscheeuwijck P; Hoeng J
Eur J Pharm Sci; 2023 Jan; 180():106321. PubMed ID: 36336278
[TBL] [Abstract][Full Text] [Related]
3. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
[TBL] [Abstract][Full Text] [Related]
4. Aerosol deposition modeling using ACSL.
Carpenter RL
Drug Chem Toxicol; 1999 Feb; 22(1):73-90. PubMed ID: 10189572
[TBL] [Abstract][Full Text] [Related]
5. Mathematical model for the selective deposition of inhaled pharmaceuticals.
Martonen TB
J Pharm Sci; 1993 Dec; 82(12):1191-9. PubMed ID: 8308694
[TBL] [Abstract][Full Text] [Related]
6. Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs.
Bäckman P; Arora S; Couet W; Forbes B; de Kruijf W; Paudel A
Eur J Pharm Sci; 2018 Feb; 113():41-52. PubMed ID: 29079338
[TBL] [Abstract][Full Text] [Related]
7. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
Boger E; Fridén M
J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):1-12. PubMed ID: 29878860
[TBL] [Abstract][Full Text] [Related]
8. Computational modeling as part of alternative testing strategies in the respiratory and cardiovascular systems: inhaled nanoparticle dose modeling based on representative aerosol measurements and corresponding toxicological analysis.
Pilou M; Mavrofrydi O; Housiadas C; Eleftheriadis K; Papazafiri P
Nanotoxicology; 2015 May; 9 Suppl 1():106-15. PubMed ID: 24295373
[TBL] [Abstract][Full Text] [Related]
9. New Approach Methodology for Assessing Inhalation Risks of a Contact Respiratory Cytotoxicant: Computational Fluid Dynamics-Based Aerosol Dosimetry Modeling for Cross-Species and In Vitro Comparisons.
Corley RA; Kuprat AP; Suffield SR; Kabilan S; Hinderliter PM; Yugulis K; Ramanarayanan TS
Toxicol Sci; 2021 Aug; 182(2):243-259. PubMed ID: 34077545
[TBL] [Abstract][Full Text] [Related]
10. Predicted Deposition of E-Cigarette Aerosol in the Human Lungs.
Sosnowski TR; Kramek-Romanowska K
J Aerosol Med Pulm Drug Deliv; 2016 Jun; 29(3):299-309. PubMed ID: 26907696
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review.
Rebello J; Brashier B; Shukla S
Daru; 2022 Jun; 30(1):229-243. PubMed ID: 35094370
[TBL] [Abstract][Full Text] [Related]
12. Simulated pharmacokinetics of inhaled caffeine and melatonin from existing products indicate the lack of dosimetric considerations.
Kolli AR; Kuczaj AK; Calvino-Martin F; Hoeng J
Food Chem Toxicol; 2024 May; 187():114601. PubMed ID: 38493979
[TBL] [Abstract][Full Text] [Related]
13. Respirable aerosol exposures of nicotine dry powder formulations to
Sciuscio D; Hoeng J; Peitsch MC; Vanscheeuwijck P
Inhal Toxicol; 2019 May; 31(6):248-257. PubMed ID: 31496314
[No Abstract] [Full Text] [Related]
14. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
15. Predicting Regional Respiratory Tissue and Systemic Concentrations of Orally Inhaled Drugs through a Novel PBPK Model.
Ladumor MK; Unadkat JD
Drug Metab Dispos; 2022 May; 50(5):519-528. PubMed ID: 35246463
[TBL] [Abstract][Full Text] [Related]
16. Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data.
Tian G; Hindle M; Lee S; Longest PW
Pharm Res; 2015 Oct; 32(10):3170-87. PubMed ID: 25944585
[TBL] [Abstract][Full Text] [Related]
17. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
Clewell HJ; Gentry PR; Gearhart JM
J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
[TBL] [Abstract][Full Text] [Related]
18. The comparative in vitro assessment of e-cigarette and cigarette smoke aerosols using the γH2AX assay and applied dose measurements.
Thorne D; Larard S; Baxter A; Meredith C; Gaҫa M
Toxicol Lett; 2017 Jan; 265():170-178. PubMed ID: 27965004
[TBL] [Abstract][Full Text] [Related]
19. The impact of pulmonary diseases on the fate of inhaled medicines--a review.
Wang YB; Watts AB; Peters JI; Williams RO
Int J Pharm; 2014 Jan; 461(1-2):112-28. PubMed ID: 24291124
[TBL] [Abstract][Full Text] [Related]
20. In vivo-in vitro correlations: predicting pulmonary drug deposition from pharmaceutical aerosols.
Byron PR; Hindle M; Lange CF; Longest PW; McRobbie D; Oldham MJ; Olsson B; Thiel CG; Wachtel H; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2010 Dec; 23 Suppl 2():S59-69. PubMed ID: 21133801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
